
Suven Life Sciences Q2 FY18 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 4- Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond.
- CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals.
- Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline.
- Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore.
- Patient enrollment for Phase-2 clinical trials is progressing, with completion expected by late 2018 and data results by mid-2019, which may impact future growth.
- Incremental growth also anticipated from preclinical compounds moving to Phase-1 clinical trials and planned Phase-2 trials for new molecules starting next year.
See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
- The management did not discuss raising capital via debt or equity during the call.
- They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means.
- The focus remains on progressing clinical trials and business growth without reference to external fundraising.
- Any future financing needs were not addressed or indicated in this transcript.
See what Suven Life Sciences management said on order book — free account, 30 seconds.
Capex plans
Yes- Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds.
- The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore.
- As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving.
- The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year.
- Total CAPEX for FY18 is expected to be around Rs. 90-100 crore.
- For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs of Rs. 20-30 crore.
- No other specific strategic investments were mentioned in this transcript.
Track Suven Life Sciences — get its next earnings analysis in your feed
How does Suven Life Sciences rank vs peers in Healthcare Services?
Pro featureHow does Suven Life Sciences rank in Healthcare Services?
Compare Suven Life Sciences against every Healthcare Services company (Q2 FY18) on revenue, margins and earnings-call signals.
Continue your research
What Suven Life Sciences's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.